ABVC BioPharma, Inc. Operating Lease Right-of-Use Assets
ABVC BioPharma, Inc. (ABVC) had Operating Lease Right-of-Use Assets of $1.74 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-08-12
- 2026-06-30: Operating Lease, Right-of-Use Asset $1.74M.
- 2026-03-31: Operating Lease, Right-of-Use Asset $1.83M.
- 2025-12-31: Operating Lease, Right-of-Use Asset $1.91M.
- 2025-09-30: Operating Lease, Right-of-Use Asset $369.13K.
| Period end | Operating Lease, Right-of-Use Asset |
|---|---|
| 2026-06-30 | $1.74M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $1.83M 10-Q · filed 2026-05-18 |
| 2025-12-31 | $1.91M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $369.13K 10-Q/A · filed 2026-03-03 |
| 2025-06-30 | $459.32K 10-Q · filed 2025-08-13 |
| 2025-03-31 | $533.46K 10-Q · filed 2025-04-30 |
| 2024-12-31 | $640.39K 10-Q/A · filed 2026-03-03 |
| 2024-09-30 | $507.66K 10-Q · filed 2024-11-14 |
| 2024-06-30 | $607.00K 10-Q · filed 2024-08-14 |
| 2024-03-31 | $708.02K 10-Q · filed 2024-05-17 |
| 2023-12-31 | $809.28K 10-K · filed 2025-04-15 |
| 2023-09-30 | $899.82K 10-Q · filed 2023-11-15 |
| 2023-06-30 | $999.64K 10-Q · filed 2023-08-14 |
| 2023-03-31 | $1.10M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $1.16M 10-K · filed 2024-03-13 |
| 2022-09-30 | $1.24M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $1.29M 10-Q · filed 2022-08-15 |
| 2022-03-31 | $1.38M 10-Q · filed 2022-05-16 |
| 2021-12-31 | $1.47M 10-K · filed 2023-03-31 |
| 2021-09-30 | $1.55M 10-Q · filed 2021-11-15 |
| 2021-06-30 | $1.64M 10-Q · filed 2021-08-12 |
| 2021-03-31 | $1.71M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $1.77M 10-K · filed 2022-03-31 |
| 2020-09-30 | $1.84M 10-Q · filed 2020-11-17 |
| 2020-06-30 | $383.09K 10-Q · filed 2020-08-14 |
| 2020-03-31 | $449.68K 10-Q · filed 2020-06-29 |
| 2019-12-31 | $524.45K 10-K · filed 2021-03-16 |
| 2019-09-30 | $357.93K 10-Q · filed 2019-11-18 |
| 2019-06-30 | $431.39K 10-Q · filed 2019-08-09 |
| 2019-03-31 | $505.31K 10-Q · filed 2019-05-28 |